PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
PTC Therapeutics (PTCT) Posts Smaller-than-Expected Q2 Loss on Much Higher Revs; Raises Outlook
August 8, 2017 4:51 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($0.44), $0.84 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $45.8 million versus the consensus estimate of $28.78 million.
2017 Guidance:
Translarna net sales for 2017 are now anticipated to be between $120 and $140 million,... More